首页 › 基金 › Melqart Asset Management (UK) Ltd › CYTK
Melqart Asset Management (UK) Ltd 对 CYTK 的持仓历史
CYTOKINETICS INC · 医疗保健
Melqart Asset Management (UK) Ltd 在 Q3 2026 的 13F 申报中披露持有 CYTK(CYTOKINETICS INC)761,539 股,市值约 US$50.2M,约占其申报组合的 5.15%,在其申报持仓中市值排名第 4 位。 Melqart Asset Management (UK) Ltd 最近 11 个申报季度中有 11 个季度披露了 CYTK 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Melqart Asset Management (UK) Ltd 对 CYTK 的持仓演变
Melqart Asset Management (UK) Ltd 于 Q1 2024 首次披露 CYTK 持仓:800,100 股(约 US$56.1M)。 该持仓在 Q2 2024 达到峰值 1,675,785 股,市值约 US$90.8M。 在 11 次申报中,Melqart Asset Management (UK) Ltd 3 次增持、7 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 761,539 股、市值约 US$50.2M,环比减持 -5,986 股。。 持仓曾出现大幅变动:Q2 2024 增持约 109% (随后一个季度股价下跌 3%)、Q3 2025 减持约 41% (随后一个季度股价上涨 16%)、Q1 2026 增持约 35% (随后一个季度股价上涨 29%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 800.10K | $56.10M | 新进 |
| Q2 2024 | 1.68M | $90.79M | 增持 |
| Q3 2024 | 1.21M | $64.01M | 减持 |
| Q4 2024 | 1.14M | $53.46M | 减持 |
| Q1 2025 | 999.45K | $40.17M | 减持 |
| Q2 2025 | 1.33M | $43.83M | 增持 |
| Q3 2025 | 783.77K | $43.08M | 减持 |
| Q4 2025 | 622.90K | $39.58M | 减持 |
| Q1 2026 | 843.95K | $55.62M | 增持 |
| Q2 2026 | 767.52K | $65.39M | 减持 |
| Q3 2026 | 761.54K | $50.19M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CYTK 与 13F 数据
CYTK(CYTOKINETICS INC)属于医疗保健行业。我们追踪的基金中还有 39 只申报持有 CYTK,申报仓位最大的包括:T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$323.0M), Polar Capital Holdings Plc (US$227.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CYTK 的基金
- T. Rowe Price Investment Management, Inc. 18.72M 股 · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 4.90M 股 · $322.96M · Q3 2026
- Polar Capital Holdings Plc 9.64M 股 · $227.69M · Q3 2026
- RTW INVESTMENTS, LP 2.86M 股 · $188.63M · Q3 2026
- Frazier Life Sciences Management, L.P. 1.16M 股 · $98.81M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.18M 股 · $77.79M · Q3 2026
- Integral Health Asset Management, LLC 1.60M 股 · $72.50M · Q3 2026
- GW&K Investment Management, LLC 1.02M 股 · $67.08M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 980.39K 股 · $64.62M · Q3 2026
- Foresite Capital Management IV, LLC 714.70K 股 · $60.88M · Q2 2026
- Affinity Asset Advisors, LLC 750.00K 股 · $49.43M · Q3 2026
更多关于 Melqart Asset Management (UK) Ltd
常见问题
How long has Melqart Asset Management (UK) Ltd held CYTK?
Melqart Asset Management (UK) Ltd has disclosed CYTK holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Melqart Asset Management (UK) Ltd's current position in CYTK?
As of Q3 2026, Melqart Asset Management (UK) Ltd holds 761.54K shares of CYTK (CYTOKINETICS INC), valued at $50.19M, representing 5.15% of its reported portfolio and ranking #4.
Has Melqart Asset Management (UK) Ltd been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Melqart Asset Management (UK) Ltd reduced its position in CYTK. The position peaked in Q2 2024 at 1.68M shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, Polar Capital Holdings Plc, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.